Prognosis
Quest Sees Direct-to-Consumer Testing Taking Off Post-Pandemic
- DTC market could bring in $250 million in revenue by 2025
- Covid-19 cited as a catalyst for a shifting test market
This article is for subscribers only.
Commercial laboratory Quest Diagnostics Inc. sees a growing direct-to-consumer testing opportunity following the Covid-19 pandemic, as patients seek greater control of their health care and the crisis accelerates a shift to digital technologies.
Direct-to-consumer testing for medical needs like colorectal cancer and others could bring in $250 million in revenue for Quest by 2025 in a total market worth about $2 billion, the company said at its investor day on Thursday.